Your browser doesn't support javascript.
loading
Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose
Pereira, Rosa M.R.; Dagostin, Marilia A.; Caparbo, Valeria F.; Sales, Lucas P.; Pasoto, Sandra G.; Silva, Clovis A.; Yuki, Emily F.N.; Saad, Carla G.S.; Medeiros-Ribeiro, Ana C.; Kupa, Leonard V.K.; Fusco, Solange R.G.; Martins, Victor A.O.; Martins, Carolina C.M.F.; Barbas, Carmen Valente; Shinjo, Samuel K.; Aikawa, Nadia E.; Bonfa, Eloisa.
Afiliación
  • Pereira, Rosa M.R.; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Dagostin, Marilia A.; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Caparbo, Valeria F.; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Sales, Lucas P.; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Pasoto, Sandra G.; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Silva, Clovis A.; Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Yuki, Emily F.N.; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Saad, Carla G.S.; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Medeiros-Ribeiro, Ana C.; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Kupa, Leonard V.K.; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Fusco, Solange R.G.; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Martins, Victor A.O.; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Martins, Carolina C.M.F.; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Barbas, Carmen Valente; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Shinjo, Samuel K.; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Aikawa, Nadia E.; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
  • Bonfa, Eloisa; Universidade de São Paulo (HCFMUSP). Faculdade de Medicina. Hospital das Clínicas. São Paulo. BR
Clinics ; Clinics;78: 100150, 2023. tab, graf
Article en En | LILACS-Express | LILACS | ID: biblio-1421262
Biblioteca responsable: BR1.1
ABSTRACT
Abstract

Objective:

To evaluate inactivated CoronaVac prime vaccination, antibody decay, booster dose, and safety in ANCA-Associated Vasculitis (AAV) patients.

Methods:

Fifty-three AAV patients and 106 Controls (CG) received CoronaVac on days D0 (first dose), D28(second dose), and D210 (booster dose, 32 AAV 32 CG). The primary outcome was immunogenicity after the second vaccine dose (day 69) assessed by Seroconversion Rates (SC) of anti-SARS-CoV-2 S1/S2 IgG and Neutralizing Antibodies (NAb). Secondary outcomes were safety, immunogenicity (D28/D240), 6-months antibody decay (D210) and the booster dose response (D240).

Results:

At D69 SC (65.1% vs. 96.8%, p = 0.0001), GMT (21.3 UA/mL vs. 67.7 UA/mL, p < 0.001) and NAb- positivity (53.7% vs. 80.6%, p = 0.001) were moderate but lower in naïve-AAV patients than CG. Patients without SC used more often IS (93.3% vs. 53.3%, p = 0.015), mycophenolate mofetil (20% vs. 0%, p = 0.037) and prednisone (60.0% vs. 28.6%, p = 0.057) than seroconverted. NAb negativity in AAV patients was associated with prednisone treatment (57.9% vs. 18.2%, p = 0.015) and IS (84.2% vs. 55.0%, p = 0.046). Logistic regression analysis models showed that only prednisone was associated with lower seroconversion (OR = 0.2, 0,95% CI 0.05-0.86, p = 0.030) and with lower NAb positivity (OR = 0.2, 0,95% CI 0.05-0.88, p = 0.034). After six months (D69-D210) a decrease in IgG positivity occurred in 32 AAV patients (15.7%, p = 0.074) and 32 CG (18.7%, p = 0.041). For the NAb positivity, the 6-month decrease was not significant (p = 0.114) whereas a major reduction occurred for CG (p < 0.001). A booster dose (D240) resulted in an increment in IgG-positivity (21.9%, p = 0.023) and NAb-positivity (34.4%, p = 0.006) in AAV patients. No moderate/severe adverse events attributable to the vaccine were observed.

Conclusion:

This study provides novel data on the excellent safety and moderate immunogenicity of CoronaVac in AAV patients. A six-month mild antibody waning was observed with a good response to the booster dose, although levels remained lower than CG (CoronavRheum-NCT04754698).
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: LILACS Tipo de estudio: Risk_factors_studies Idioma: En Revista: Clinics Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article / Project document País de afiliación: Brasil

Texto completo: 1 Colección: 01-internacional Banco de datos: LILACS Tipo de estudio: Risk_factors_studies Idioma: En Revista: Clinics Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article / Project document País de afiliación: Brasil